The historical rank and industry rank for Windlas Biotech's FCF Margin % or its related term are showing as below:
NSE:WINDLAS'
s FCF Margin % Range Over the Past 10 Years
Min: -1.94 Med: 2.53 Max: 11.33
Current: 4.12
During the past 8 years, the highest FCF Margin % of Windlas Biotech was 11.33%. The lowest was -1.94%. And the median was 2.53%.
NSE:WINDLAS's FCF Margin % is ranked better than 55.53% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs NSE:WINDLAS: 4.12
Windlas Biotech FCF Margin % Related Terms
Windlas Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Windlas Biotech and its competitors. According to the industry distribution chart, Windlas Biotech ranks #426 out of 958 companies in the Drug Manufacturers industry, placing it in the top 44.5%.
Is Windlas Biotech's FCF Margin % too high?
Windlas Biotech's current FCF Margin % is 0.00%. Based on the distribution chart, Windlas Biotech ranks #426 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #426 out of 958 companies for FCF Margin %. This puts Windlas Biotech in the upper half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.27, compared to a current price of ₹855.75 — trading 8.6% below its estimated fair value. The current FCF Margin % is 0.00%. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹855.75 is trading 8.6% below its estimated GF Value™ of ₹936.27.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
FCF Margin %: 0.00%
GF Value™: ₹936.27 vs. price of ₹855.75 (8.6% below fair value)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score
Get the complete analysis for NSE:WINDLAS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
